Market Research Logo

CTI BioPharma Corp. - Product Pipeline Review - 2015

CTI BioPharma Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CTI BioPharma Corp. - Product Pipeline Review - 2015’, provides an overview of the CTI BioPharma Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CTI BioPharma Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CTI BioPharma Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CTI BioPharma Corp.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CTI BioPharma Corp.’s pipeline products
Reasons to buy
  • Evaluate CTI BioPharma Corp.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CTI BioPharma Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CTI BioPharma Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CTI BioPharma Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CTI BioPharma Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CTI BioPharma Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


CTI BioPharma Corp. Snapshot
CTI BioPharma Corp. Overview
Key Information
Key Facts
CTI BioPharma Corp. - Research and Development Overview
Key Therapeutic Areas
CTI BioPharma Corp. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
CTI BioPharma Corp. - Pipeline Products Glance
CTI BioPharma Corp. - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
CTI BioPharma Corp. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CTI BioPharma Corp. - Drug Profiles
paclitaxel poliglumex
Product Description
Mechanism of Action
R&D Progress
pixantrone dimaleate
Product Description
Mechanism of Action
R&D Progress
pacritinib
Product Description
Mechanism of Action
R&D Progress
lisofylline
Product Description
Mechanism of Action
R&D Progress
tosedostat
Product Description
Mechanism of Action
R&D Progress
CTI BioPharma Corp. - Pipeline Analysis
CTI BioPharma Corp. - Pipeline Products by Target
CTI BioPharma Corp. - Pipeline Products by Route of Administration
CTI BioPharma Corp. - Pipeline Products by Molecule Type
CTI BioPharma Corp. - Pipeline Products by Mechanism of Action
CTI BioPharma Corp. - Recent Pipeline Updates
CTI BioPharma Corp. - Dormant Projects
CTI BioPharma Corp. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CT-2584
nortopixantrone
topixantrone
CTI BioPharma Corp. - Company Statement
CTI BioPharma Corp. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
CTI BioPharma Corp., Key Information
CTI BioPharma Corp., Key Facts
CTI BioPharma Corp. - Pipeline by Indication, 2015
CTI BioPharma Corp. - Pipeline by Stage of Development, 2015
CTI BioPharma Corp. - Monotherapy Products in Pipeline, 2015
CTI BioPharma Corp. - Filing rejected/Withdrawn, 2015
CTI BioPharma Corp. - Phase III, 2015
CTI BioPharma Corp. - Phase II, 2015
CTI BioPharma Corp. - Phase I, 2015
CTI BioPharma Corp. - Pipeline by Target, 2015
CTI BioPharma Corp. - Pipeline by Route of Administration, 2015
CTI BioPharma Corp. - Pipeline by Molecule Type, 2015
CTI BioPharma Corp. - Pipeline Products by Mechanism of Action, 2015
CTI BioPharma Corp. - Recent Pipeline Updates, 2015
CTI BioPharma Corp. - Dormant Developmental Projects,2015
CTI BioPharma Corp. - Discontinued Pipeline Products, 2015
CTI BioPharma Corp., Subsidiaries
List of Figures
CTI BioPharma Corp. - Pipeline by Top 10 Indication, 2015
CTI BioPharma Corp. - Pipeline by Stage of Development, 2015
CTI BioPharma Corp. - Monotherapy Products in Pipeline, 2015
CTI BioPharma Corp. - Pipeline by Top 10 Target, 2015
CTI BioPharma Corp. - Pipeline by Top 10 Route of Administration, 2015
CTI BioPharma Corp. - Pipeline by Top 10 Molecule Type, 2015
CTI BioPharma Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report